Low-frequency repetitive transcranial magnetic stimulation on Parkinson motor function: A meta-analysis of randomised controlled trials

Acta Neuropsychiatrica

Volumn 27, Issue 2, 2015, Pages 82-89

  Zhu, Hongcan ^a   Lu, Zhaoming ^b   Jin, Yiting ^a   Duan, Xiaojia ^a   Teng, Junfang ^a   Duan, Dongxiao ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Parkinson's disease; PD; repetitive transcranial magnetic stimulation; rTMS; TMS

Indexed keywords

ADD ON THERAPY; ARTICLE; CHINA; HUMAN; ITALY; JAPAN; LOW FREQUENCY NOISE; META ANALYSIS; MOTOR DYSFUNCTION; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; UNIFIED PARKINSON DISEASE RATING SCALE; ADVERSE EFFECTS; AGED; FEMALE; MALE; MIDDLE AGED; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84927175240     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2014.43     Document Type: Article

References (37)

1. FAHN S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003; 991: 1-14.
2. DORSEY ER, CONSTANTINESCU R, THOMPSON JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384-386.
3. RASCOL O, BROOKS DJ, KORCZYN AD, DEYN DE, CLARKE CE, LANG AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-1491.
4. BENNINGER DH, BERMAN BD, HOUDAYER E et al. Intermittent theta-burst transcranial magnetic stimulation for treatment of Parkinson disease. Neurology 2011; 76: 601-609.
5. ZHU C, WANG G, LI J et al. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis. Neurol Res 2014; 36: 1028-1034.
6. DUNGO R, DEEKS ED. Istradefylline: first global approval. Drugs 2013; 73: 875-882.
7. CHEN JJ, LIU Z, ZHU D et al. Bilateral vs. unilateral repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomized controlled trials. Psychiatry Res 2014; 219: 51-57.
8. CHEN JJ, ZHOU C, WU B et al. Left versus right repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomised controlled trials. Psychiatry Res 2013; 210: 1260-1264.
9. KHEDR EM, ROTHWELL JC, SHAWKY OA, AHMED MA, HAMDY A. Effect of daily repetitive transcranial magnetic stimulation on motor performance in Parkinson's disease. Mov Disord 2006; 21: 2201-2205.
10. LOMAREV MP, KANCHANA S, BARA-JIMENEZ W, IYER M, WASSERMANN EM, HALLETT M. Placebo-controlled study of rTMS for the treatment of Parkinson's disease. Mov Disord 2006; 21: 325-331.
11. ELAHI B, ELAHI B, CHEN R. Effect of transcranial magnetic stimulation on Parkinson motor function: systematic review of controlled clinical trials. Mov Disord 2009; 24: 357-363.
12. SHIROTA Y, OHTSU H, HAMADA M, ENOMOTO H, UGAWA Y. Research Committee on rTMS Treatment of Parkinson's Disease. Supplementary motor area stimulation for Parkinson disease: a randomized controlled study. Neurology 2013; 80: 1400-1405.
13. OKABE S, UGAWA Y, KANAZAWA I. Effectiveness of rTMS on Parkinson's Disease Study Group. 0.2-Hz repetitive transcranial magnetic stimulation has no add-on effects as compared to a realistic sham stimulation in Parkinson's disease. Mov Disord 2003; 18: 382-388.
14. NIU X, GOU Y. Observation of repetitively transcranial magnetic stimulation in the treatment of depression induced by Parkinson's disease. Chinese Journal of Practical Nervous Disease 2012; 15: 11-13.
15. WANG M, GU P, MA X et al. Effects of low frequency repetitive transcranial magnetic stimulation on motor function and affective disorder in patients with Parkinson's disease. Chin J Geriatr 2009; 28: 729-732.
16. HUGHES AJ, BEN-SHLOMO Y, DANIEL SE, LEES AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-1146.
17. HIGGINS JPT, ALTMAN DG. Assessing risk of bias in included studies. In: Julian PT Higgins and Sally Green, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, A John Wiley & Sons Ltd, 2011. p. 187-243.
18. RILEY RD, HIGGINS JP, DEEKS JJ. Interpretation of random effects meta-analyses. BMJ 2011; 342: d549.
19. HIGGINS JP, THOMPSON SG, DEEKS JJ, ALTMAN DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557.
20. SACKS HS, BERRIER J, REITMAN D, ANCONA-BERK V, CHALMERS TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450.
21. SHIMAMOTO H, TAKASAKI K, SHIGEMORI M, IMAIZUMI T, AYABE M, SHOJI H. Therapeutic effect and mechanism of repetitive transcranial magnetic stimulation in Parkinson's disease. J Neurol 2001; 248(Suppl. 3): III48-III52.
22. KOCH G, BRUSA L, CALTAGIRONE C et al. rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. Neurology 2005; 65: 623-625.
23. ZHANG H, DAI Y, SU M, LUO W, C. Clinical study of treating Parkinson disease by repetitive transcranial magnetic stimulation. J Clin Neulo 2005; 18: 266-269.
24. ZHONG Y, SHIMAMOTO H, SHIGEMORI M. Repetitive transcranial magnetic stimulation in Parkinson's disease. Mod J Neurd Neurosurg 2003; 3: 228-230.
25. DE LAU LM, BRETELER MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-535.
26. XIE J, CHEN J, WEI Q. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a meta-analysis of stimulus parameter effects. Neurol Res 2013; 35: 1084-1091.
27. FITZGERALD PB, FOUNTAIN S, DASKALAKIS ZJ. A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clin Neurophysiol 2006; 117: 2584-2596.
28. ELDAIEF MC, HALKO MA, BUCKNER RL, PASCUAL-LEONE A. Transcranial magnetic stimulation modulates the brain's intrinsic activity in a frequency-dependent manner. Proc Natl Acad Sci USA 2011; 108: 21229-21234.
29. WASSERMANN EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the Inter-national Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation. Electroencephalogr Clin Neurophysiol 1998; 108: 1-16.
30. CHEN R, GERLOFF C, CLASSEN J, WASSERMANN EM, HALLETT M, COHEN LG. Safety of different inter-train intervals for repetitive transcranial magnetic stimulation and recommendations for safe ranges of stimulation parameters. Electroencephalogr Clin Neurophysiol 1997; 105: 415-421.
31. SCHUTTER D. Quantitative review of the efficacy of slowfrequency magnetic brain stimulation in major depressive disorder. Psychol Med 2010; 40: 1789.
32. EIDELBERG D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009; 32: 548-557.
33. PLAYFORD ED, JENKINS IH, PASSINGHAM RE, NUTT J, FRACKOWIAK RS, BROOKS DJ. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992; 32: 151-161.
34. SABATINI U, BOULANOUAR K, FABRE N et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000; 123: 394-403.
35. WASSERMANN EM, ZIMMERMANN T. Transcranial magnetic brain stimulation: therapeutic promises and scientific gaps. Pharmacol Ther 2012; 133: 98-107.
36. ROSA MA, LISANBY SH. Somatic treatments for mood disorders. Neuropsychopharmacology 2012; 37: 102-116.
37. SCHÖNFELDT-LECUONA C, LEFAUCHEUR JP, CARDENAS-MORALES L, WOLF R, KAMMER T, HERWIG U. The value of neuronavigated rTMS for the treatment of depression. Neurophysiol Clin 2010; 40: 37-43.